



# ATN 173/HPTN 115: The foXXy doxy Study

## Study Description

Doxycycline is a well-known, **FDA-approved antibiotic** that is widely used to prevent and treat acne and certain sexually transmitted infections (STIs) like gonorrhea, chlamydia, and syphilis.

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Women in the United States (The foXXy doxy Study) is trying to find out **if taking doxycycline either after condomless sex (on-demand) or weekly, known as “DoxyPEP,” can reduce STI rates for women** when compared to standard STI testing, treatment, and sexual health counseling. All participants will have access to a **mobile health app** that includes simple tools to record their health information (e.g., sexual behavior, doxycycline use).

## Who may be eligible?

Women ages 13-29 who have had an STI (gonorrhea, chlamydia, or syphilis) in past 12 months

## Where is the study enrolling?

**Atlanta** | Ponce De Leon Center  
**Chapel Hill** | University of North Carolina at Chapel Hill  
**Chicago** | University of Illinois Chicago  
**Houston** | Baylor College of Medicine/Texas Children’s Hospital  
**Los Angeles** | University of California Los Angeles  
**Memphis** | St. Jude Children’s Research Hospital  
**New Orleans** | Tulane University  
**New York City** | Harlem Prevention Center  
**Philadelphia** | University of Pennsylvania  
**San Francisco** | Bridge HIV  
**Tampa** | University of South Florida  
**Washington, D.C.** | Children’s National Hospital

## Why is this study important?

STI rates are rising, with over half of STIs occurring among individuals 15-24 years old. **Bacterial STIs can have negative impacts**, especially among women, due to **severe uterine infections, chronic pelvic pain, infertility, etc.**

DoxyPEP is approved for men, but **DoxyPEP is not yet approved for women because there is not enough research** around how effective DoxyPEP is for this population. The foXXy doxy study is designed to support and better understand how participants take doxycycline so they can take the necessary doses to prevent STIs. We hope to show that doxyPEP prevents STIs among adolescent and young people regardless of who they are.

Women are **often left out of HIV and STI prevention interventions**. If DoxyPEP prevents STIs in the foXXy doxy study, it will **inform policy and provide an effective STI prevention tool** to incorporate into patient care.

## ClinicalTrials.gov Information

[NCT06738407](https://clinicaltrials.gov/ct2/show/study/NCT06738407)

## Questions? Contact Us!

**Site:**

**Project Lead:**

**Email:**

**Phone Number:**